Bracco Imaging
Bracco Imaging specializes in the development and marketing of diagnostic imaging agents for various medical imaging modalities, including X-ray, computed tomography, nuclear medicine, and magnetic resonance imaging (MRI). The company offers a range of products, such as Isovue, an iopamidol injection for X-ray and CT imaging, and ProHance, a gadolinium-based contrast agent for MRI. In nuclear medicine, Bracco provides agents like CardioGen-82 for myocardial perfusion imaging and Choletec for hepatobiliary imaging. Additionally, the company produces gastroenterology-related products and ultrasound contrast agents, enhancing the safety and efficacy of diagnostic procedures. Founded in 1994 and based in Princeton, New Jersey, Bracco Imaging operates as a subsidiary of Bracco S.p.A., focusing on improving patient care through advanced imaging solutions and professional services for healthcare providers.
Blue Earth Diagnostics to develop and commercialise molecular imaging agents addressing areas of high un-met medical need. The company is named after Blue Earth County, Minnesota where Sir Henry Wellcome (1853-1936), the founder of the Wellcome Trust, spent his childhood. Wellcome was one of the most fascinating men of his time. A businessman, collector and philanthropist, he was born in the American Wild West but ended his days as a knight of the British Realm. He co-founded a multinational pharmaceutical company that mastered modern techniques of advertising such as promotion, image and branding. He also funded pioneering medical research, in his lifetime, scientists funded by Wellcome made great breakthroughs into understanding how our bodies work. After his death the great man’s will provided for the creation of the Wellcome Trust, whose venture investment arm Syncona Partners LLP (“Syncona”) are the founding investors in BED.
SurgVision BV develops near-infrared fluorescence molecular imaging technology solutions. It offers Multi-Spectral Normalized Imaging, a platform that makes fluorescence imaging of molecular probes for clinical use. The company was incorporated in 2011 and is based in 't Harde, the Netherlands. As of October 18, 2017, SurgVision BV operates as a subsidiary of Bracco Imaging S.p.A..
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.